Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The significance of the relationship between the microbiota and diseases is increasingly being recognized. However, the characterization of tumor microbiome and their precise molecular mechanisms through which microbiota promotes hepatocellular carcinoma (HCC) development are still unclear.
Methods: The intrahepatic microbiota was investigated from tumor, normal adjacent tissues in 46 patients with HCC and normal hepatic tissues in 33 patients with hemangioma by 16S rRNA gene sequencing. Taxonomic composition differences in patients were evaluated using Linear discriminant analysis Effect Size (LefSe) and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) to predict microbial functional pathways. Associations between the most relevant taxa and clinical characteristics of HCC patients were analyzed by Spearman rank correlations. The effects of microbe on hepatic stellate cells (HSCs) activation and HCC progression were examined.
Results: We observed intrahepatic microbiota disturbances by reduced microbial diversity in HCC. The tumor microbiota of the HCC patients with cirrhosis showed higher abundance of . provoked senescence-associated secretory phenotype (SASP) in HSCs by activating TLR-4-mediated NF-κB signaling pathway, which in turn induced NLRP3 inflammasome complex formation and secreted various inflammatory factors in the liver, thus facilitating HCC progression in mice. Moreover, signs of SASP were also observed in the HSCs in the area of HCC with higher enrichment arising in patients with cirrhosis.
Conclusions: Our analysis of the hepatic microbiota revealed for the first time that patients with HCC exhibited a dysbiotic microbial community with higher abundance, which induced the expression SASP factors of HSCs and cirrhosis in the liver, concurring in the process of hepatocarcinogenesis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744134 | PMC |
| http://dx.doi.org/10.1136/jitc-2021-003069 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hesperetin alleviates liver fibrosis by improving intestinal microbiota composition and regulating hepatic stellate cell autophagy.
Eur J Pharmacol
August 2025
Center for tissue Engineering and Stem Cell Research, Guizhou Medical University, China; Department of Pharmacology, School of Basic Medicine, Guizhou Medical University, China. Electronic address:
Liver fibrosis can be commonly observed in numerous chronic liver diseases. Disruptions in the gut microbiota aggravate liver injury and fibrosis. Autophagy is an intracellular catabolic and recycling process regulated by lysosome, which has a vital impact on maintaining normal liver function.
View Article and Find Full Text PDFGenomic Alterations and Microbiota Crosstalk in Hepatic Cancers: The Gut-Liver Axis in Tumorigenesis and Therapy.
Genes (Basel)
July 2025
Cell and Tissue Biology Group, Anatomy and Cell Biology Department, University of Cantabria-IDIVAL, 39011 Santander, Spain.
Hepatic cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), are major global health concerns due to rising incidence and limited therapeutic success. While traditional risk factors include chronic liver disease and environmental exposures, recent evidence underscores the significance of genetic alterations and gut microbiota in liver cancer development and progression. This review aims to integrate emerging knowledge on the interplay between host genomic changes and gut microbial dynamics in the pathogenesis and treatment of hepatic cancers.
View Article and Find Full Text PDFBackground: Liver transplantation (LT) remains hampered by post-transplant complications. While gut microbiota dysbiosis has been linked to transplant outcomes, the role of the intrahepatic graft's native microbiota remains unexplored.
Objective: To characterise the microbial profile detected in organ preservation solution (OPS) and determine whether specific microbial taxa are associated with short-term clinical outcomes, and to develop predictive models for risk stratification.
Beta-Catenin Mutations Can Impact on the Interplay Between Tumor and Immune Cells and Hepatic Microbiota in Hepatocellular Cancer.
J Hepatocell Carcinoma
August 2025
Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA.
Introduction: Emerging evidence links alterations in the tumor microbiome to therapeutic responses to immunotherapy. Alterations in β-catenin are among the most frequently observed oncogenic drivers of hepatocarcinogenesis and are associated with T-cell exclusion. However, their effect on the immune cell environment and microbiome in hepatocellular cancer is not well understood.
View Article and Find Full Text PDFA New Dimension in Tumor Heterogeneity: Intratumoral Bacteria Impact Multifocal Hepatocellular Carcinoma Development.
Cancer Discov
August 2025
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Lu and colleagues identified profound microbial heterogeneity across individual tumor nodules in multifocal hepatocellular carcinoma, revealing that specific bacterial consortia enrich in metastatic clones and drive epithelial-mesenchymal transition and immune suppression. Their study places the intratumoral microbiome alongside genomic and transcriptomic diversity as a key modulator of intrahepatic tumor evolution. See related article by Lu et al.
View Article and Find Full Text PDF